TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Rate of adherence to recommended home OSA evaluation and treatment
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Functional connectivity of hippocampus and DLPFC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Visible Surface Area of the Lipoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Imaging effect of indocyanine green
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of significant fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Total Venous Thrombo Embolism (VTE)
Endpoint domain: Mortality/survival
Primary endpoint: Deep Vein Thromboembolism (DVT)
Endpoint domain: Adverse events/effects
Primary endpoint: Non Fatal Pulmonary Embolism (PE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Safely Treated Participants
Endpoint domain: Adverse events/effects
Primary endpoint: Ratio of MDSC Concentration in the Blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Ratio of T-reg Cell Concentration in the Blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Ratio of Tumor-specific T-cell Concentration in the Blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in immune profile of blood and tissue after radiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Adenoma detection rate (for all colonoscopies)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Screening Adenoma detection rate (Screening colonoscopies only)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Subjects Experiencing Tourniquet Hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Low Density Lipoprotein Cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of participants with death from any cause
Endpoint domain: Mortality/survival
Primary endpoint: Number of participants with pre-specified adjudicated cardiovascular serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Dyspnea with ADL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Exercise and functional performance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Acute COPD exacerbations
Endpoint domain: Adverse events/effects
Primary endpoint: Hematological Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Quality of saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oral flora
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RBC Transfusions Per Subject Receiving a Transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Relative hazard of venous thromboembolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number of specific endogenous peptides
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti-myeloma response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Burden of hypertension, diabetes, and hyperlipidaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Central Subfield Volume (CSV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Best Corrective Visual Acuity (BCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose of Stereotactic Body Radiotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: Primary Tumor Control Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Production of 1,25OHD3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: anterior segment SD-OCT findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Surgical Site Infection (SSI)
Endpoint domain: Adverse events/effects
Primary endpoint: Good quality blastocyst on Day 5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Cardiovascular Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of Cardiovascular Morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Identification of melanoma and severe/high-grade dysplasia lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Hamilton depression (HAMD) rating scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pre-Hemodialysis Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Annualized height velocity (AHV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastrointestinal response to a meal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Changes in INR/PT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in serum AST levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in serum ALT levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in TB levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Early-onset Primary Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in experienced quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Sural Nerve Function measured by conduction velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in level of pain with painDETECT questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: elimination of bacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Area Under the Concentration Versus Time Curve From Zero to Infinity After a Single Dose (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Drug Concentration in Measured Matrix After a Single Dose (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Happiness levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Satisfaction with life levels
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Loneliness levels
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Somatisation levels
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of Participants Who Achieved an ACR 20 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Prioritized Healthcare Topics
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Participants Who Prioritized Research Topics
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Diagnostic ability to diagnose hemorrhagic stroke and ischemic stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Successful EUS-B-FNA procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change from Baseline in the Liebowitz Social Anxiety Scale (LSAS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Differentiation of benign pancreatic cysts from malignant potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Identification rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of portal/splenic vein thrombosis
Endpoint domain: Adverse events/effects
Primary endpoint: Early epithelial somatic mutations/indels in precancerous breast ducts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: functional magnetic resonance imaging (fMRI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eligibility to lung harvest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant enrolment rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence of IED
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Patient Satisfaction With Medication for Pain
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Average Pain Intensity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Negative biopsy in the treated lobes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Accuracy of placental site/gestational sac implantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Expression of virulence factors of S. aureus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antibiotics concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression of genomic alterations of S. aureus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patency time of large plastic biliary stents
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Complete Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in stress level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Pain scoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative incidence of gastric variceal rebleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change from baseline 10-meter walking speed test at 3-months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline 5 times sit to stand test at 3-months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate (CR or PR)
Endpoint domain: Physiological/clinical
Primary endpoint: change of gut microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: change of host metabolite concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pennation angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Presence of Major Depressive Episode, Dysthymia or Depressive Disorder NOS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the ROC curve of the CVPV-st parameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Discontinuation - Emergent Signs and Symptoms (DESS) Score
Endpoint domain: Adverse events/effects
Primary endpoint: Risk Awareness and Recall
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient Reported Use of Opioid Medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Lp-PLA2 Activity in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Lp-PLA2 Activity in PBMC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Neuroradiological findings from brain MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of GEP-NET in Italy
Endpoint domain: Mortality/survival
Primary endpoint: Fat Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with treatment emergent adverse events leading to dose modifications
Endpoint domain: Adverse events/effects
Primary endpoint: Freedom From Any Episode of Post Operative Atrial Fibrillation Longer Than 6 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prognosis related to tumor-associated macrophages
Endpoint domain: Mortality/survival
Primary endpoint: Change from baseline of Breast-Q questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Area Under the Plasma Concentration-time Curve (AUC[0-infinity]) of DTG for Part 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Concentration (Cmax) of DTG for Part 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive resection margin(s) in the final histopathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Re-excision-rate during primary breast conserving surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of repeat surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Reduction of Anterior/Posterior Axilla Fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cervical spine mechanical analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cervical spine functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerance of medications
Endpoint domain: Adverse events/effects
Primary endpoint: Ocular redness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morbidity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Satisfaction With Asthma Treatment Questionnaire (SATQ) Scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 1-grade Improvement on CR-SMFRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2-grade Improvement on CR-SMFRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Device, Drug or Procedure-related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Patients With Clearing of Conjunctival Erythema and Discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects achieving 25-OH-D levels ≥ 30 ng/mL and/or ≥ 20 ng/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Streptococcus pneumoniae serotype carriage rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Eradication rates of Helicobacter pylori infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Ability to dissect adherences without cutting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: 12-week sustained virologic response (SVR12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Behavior change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: N-back task
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Stop-signal task
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Patient Follow-up form
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Tumor volume in each MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: T2 signal intensity of tumor in each MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Total Volume Dispensed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose limiting toxicities
Endpoint domain: Adverse events/effects
Endpoint subdomain: Any subdomain
Primary endpoint: Mean pain score during intrauterine device insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative test result for COVID-19
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: HIV DNA level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of determinants privileged by patients
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Type of determinants privileged by patients
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Calcium absorption rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in frequency of total satisfying sexual activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Frequency of patient-reported vaginal and urinary symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in UPDRS Parts II+III Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Inflammation Biomarker Tissue PGE2 Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Esophageal Inflammation Biomarker COX-2 Gene Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Difference of species distribution of microorganism according to 16s RNA analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Difference of species distribution of microorganism according to microculture outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to hypoglycaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Success Rate of Transnasal Endoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T-cell response against MVA-BN and the Nef antigen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Non-detection rate of hepatitis B virus DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Epoetin alfa utilization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Plasma drug concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Manual Muscle Test (Medical Research Council scale-MRC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Hammersmith Motor Ability Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Amount of Pain Experienced
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Proportion of Women With PMDD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Zinc coverage for acute childhood diarrhoea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of repeated HF hospitalizations, urgent HF Visits, and cardiovascular death
Endpoint domain: Mortality/survival
Primary endpoint: Performance of miRNA profiling from tumor samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Assessment of miRNA profiles from blood/serum samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation of classic tumor markers with tumor stage and grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Anti-nicotine Antibody concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose (MTD) of EZN-2968
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in serum Vitamin D2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Antibody titers to the P. falciparum circumsporozoite repeat domain (anti-CS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Subjects With Clinically Significant Change From Baseline in Clinical Laboratory Tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prediction accuracy of femoral vein location
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EPIC score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Chronic pain improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Procedural access-related complications
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Tolerated Dose (MTD) of CD19-specific T-cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary variable
Endpoint domain: null
Endpoint subdomain: null
Primary endpoint: IOL position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes